Planned Parenthood and other providers got word in March that millions they anticipated in Title X funding would be withheld. The money was eventually released last year, though some providers say damage was still done. (Getty Images)

Planned Parenthood clinics in Utah resumed family planning services after the Trump administration unfroze millions in federal funds.

The American Civil Liberties Union on Tuesday submitted a brief to dismiss a lawsuit filed on behalf of the National Family Planning and Reproductive Health Association after the federal government notified nine Planned Parenthood affiliates and other family planning providers in March it would withhold annual Title X funding. 

Shireen Ghorbani, president and CEO of Planned Parenthood Association of Utah, said in a statement Monday that the restored funding does not erase all of the damage caused by nine months without it. Title X funds are meant to provide affordable family planning services, such as birth control, cancer screening, and STI tests and treatment. 

Ghorbani noted that the Utah affiliate has been the only Title X grant recipient in the state since 1985. 

“We are thrilled that Title X funding is restored to Utah for now, allowing more Utahns to get critical family planning services,” Ghorbani said. “But we cannot ignore the fact that too many Utahns have already felt the devastating effects of the Trump administration’s unwarranted decision to withhold this funding for the last nine months. Many of the 26,000 Utahns who rely on the program were forced to pay more for their health care or go without care altogether.”

Crucially, she said, the affiliate closed two health centers, in St. George and Logan, among dozens that have closed because of the withheld Title X funding and are unlikely to reopen, according to Planned Parenthood. 

Some grantees had their funding restored over the summer, Politico reported, while others remained under investigation for possibly violating the Trump administration’s new rules around so-called diversity, equity and inclusion practices until December. That’s when the U.S. Department of Health and Human Services informed Planned Parenthood affiliates that they would receive their promised funds dating back to last April, with no explanation beyond unspecified “clarifications made by, and actions taken by, the grantees.” 

Planned Parenthood’s Utah affiliate said that on Jan. 9 it received $2 million in Title X funding for the current grant year that had been withheld since April.

In the lawsuit over the Title X funding, plaintiffs argued that the federal government withholding 22 federal Title X grants from Planned Parenthood and other family planning organizations was illegal and unjustified. 

“Our lawsuit succeeded in holding the administration accountable for its unlawful acts, and today, NFPRHA members’ grants have been restored. We are relieved all of our members now have access to their promised funds, but we know the fight for contraceptive access in this country goes on,” said Clare Coleman, president & CEO of the National Family Planning and Reproductive Health Association, in a statement Tuesday. 

She estimated that 865 family planning service sites were unable to provide Title X-funded services to an estimated 842,000 patients across nearly two dozen states.

While some states have fought to restore Title X family planning funding, Idaho last year declined its annual $1.5 million federal Title X funding, leaving patients statewide without free and low-cost contraception and reproductive health care services.

At least 20 more Planned Parenthood clinics have also closed because of last year’s budget reconciliation bill, which effectively blocked Planned Parenthood and other nonprofit reproductive health care providers from being able to participate in Medicaid, reducing low-income health care options throughout the country. Litigation remains ongoing in several cases over that Medicaid rule.

A preschool teacher prepares lunch for students inside a day care center. (Photo by Billy Hustace/Getty Images)

WASHINGTON — States must now provide “justification” that federal child care funds they receive are spent on “legitimate” providers in order to get those dollars, President Donald Trump’s administration announced. 

The Tuesday shift in policy came following allegations of fraud in Minnesota’s child care programs, which prompted the U.S. Department of Health and Human Services to freeze all child care payments to the state. 

HHS could not offer many specifics on how the review process will play out for other states, but clarified that the money in question is provided through the multibillion-dollar federal Child Care and Development Fund, or CCDF. 

“States will be required to provide documentation, such as written justification, receipts, or photographic evidence, demonstrating that funds are supporting legitimate child care providers,” Emily Hilliard, a spokesperson for HHS, said in a statement to States Newsroom on Wednesday. 

CCDF provides federal funding to states, territories and tribes to help low-income families obtain child care. 

The program, administered within the Office of Child Care under HHS’ Administration for Children and Families, combines funding from the Child Care and Development Block Grant, or CCDBG, and the Child Care Entitlement to States, or CCES. 

Funding for CCDF in fiscal year 2025 stood at roughly $12.3 billion — comprising $8.75 billion from CCDBG and $3.55 billion from CCES. 

Head Start — a separate program that provides early childhood education, nutritious meals, health screenings and other support services to low-income families — does not appear to be affected. 

In a Tuesday social media post announcing the move, Health and Human Services Deputy Secretary Jim O’Neill said he had “activated our defend the spend system for all ACF payments” and “starting today, all ACF payments across America will require a justification and a receipt or photo evidence before we send money to a state.” 

He clarified in a separate post shortly after that “funds will be released only when states prove they are being spent legitimately.” 

Funds undergo ‘regular audits’

“Federal funding enables millions of parents in every state and Congressional district to access and afford quality child care,” Sarah Rittling, executive director of First Five Years Fund, a federal advocacy group, said in a Wednesday statement. 

Rittling added that “these funds are essential to the nation’s well-being, allowing parents to work while ensuring their children are cared for and safe.” 



She also described the reports of potential fraud as “deeply concerning” and pointed out that “state oversight through regular audits is required by law to ensure that every dollar intended to protect and support young children is used properly and effectively.” 

“At the same time, we must ensure that nothing takes away from making sure funds for child care continue to reach the children and families who depend on them,” she said. 

Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz speaks at the Department of Health and Human Services in Washington, D.C., on Dec. 18, 2025. Oz and other Trump administration officials announced proposed rules that would limit gender-affirming care for minors. (Photo by Alex Wong/Getty Images)

WASHINGTON — President Donald Trump’s administration took major steps Thursday in a campaign to block minors’ access to gender-affirming care nationwide. 

Under two proposed new rules from the Centers for Medicare and Medicaid Services, hospitals would be barred from providing gender transition treatment for children as a condition of participating in Medicare and Medicaid programs, and Medicaid funding would be prohibited from being used to fund such care for minors. 

As most hospitals receive Medicare and Medicaid funding, the rules would essentially have the effect of a nationwide ban if they are finalized. 

The announcement came a day after the U.S. House passed a bill that would impose federal criminal penalties for gender-affirming care for minors and hours before it advanced a separate measure that would prohibit Medicaid funding for gender transition treatment for minors. 

The proposed regulations, which will next undergo a period of public comments, are certain to draw legal challenges.

The efforts build on Trump’s executive order in January that restricted access to gender-affirming care for kids. 

More than half of states already have laws or policies aimed at limiting youth access to gender-affirming care, according to the nonpartisan health research organization KFF. 

Health and Human Services Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz announced the proposals alongside several other health officials at a press conference at HHS headquarters in Washington, D.C. 

The room featured a handful of GOP members of Congress. At least two Republican state attorneys general — Ken Paxton of Texas and Todd Rokita of Indiana — were also in attendance.

At the press conference, Food and Drug Administration Commissioner Dr. Marty Makary said the FDA is also sending “warning letters” to 12 breast binder manufacturers and sellers for “illegal marketing of breast binders for children for the purposes of treating gender dysphoria.” 

Breast binders are used to flatten tissue in the chest.  

Kennedy said his agency’s Office for Civil Rights is moving to “reverse the Biden administration’s attempt to include gender dysphoria within the definition of disability.” 

House passes anti-transgender bills 

The proposed rules are part of the Trump administration’s broader anti-trans agenda. 

Trump has signed executive orders that make it the “policy of the United States to recognize two sexes, male and female,” aimed to bar openly transgender service members from the U.S. military, and sought to prohibit trans athletes from competing on women’s sports teams consistent with their gender identity.

Meanwhile, efforts at the congressional level to restrict youth access to gender-affirming care face a dismal path in the Senate, where any legislation would likely need the backing of at least 60 senators to advance past the filibuster.

The House passed a measure Wednesday night, 216-211, that would subject medical professionals to up to 10 years in prison for providing gender-affirming care for minors. 

Rep. Marjorie Taylor Greene, who sponsored the legislation, called its passage a “win for children all over America,” in a social media post Wednesday. 

It’s likely the last legislative achievement for the Georgia Republican, who is resigning from Congress in early January. 

Four Republicans voted against the measure: Reps. Gabe Evans of Colorado, Brian Fitzpatrick of Pennsylvania, Mike Kennedy of Utah and Mike Lawler of New York.

Three Democrats voted with the GOP to back the bill: Reps. Henry Cuellar and Vicente Gonzalez of Texas and Don Davis of North Carolina.

The House also passed a measure Thursday, 215-201, from Texas GOP Rep. Dan Crenshaw and Greene that aims to prohibit “Medicaid funding for gender transition procedures for minors.” 

Cuellar, Gonzalez and Davis also backed the GOP-led bill, along with fellow Democratic Rep. Marie Gluesenkamp Perez of Washington state. 

‘Cruel and unconstitutional attacks’ 

Kelley Robinson, president of the Human Rights Campaign, an LGBTQ+ advocacy group, blasted the administration’s proposals, saying they “would put Donald Trump and RFK Jr. in those doctor’s offices, ripping health care decisions from the hands of families and putting it in the grips of the anti-LGBTQ+ fringe.”  

Robinson also emphasized that the rules are “proposals, not binding law,” and called on community members, health care providers, administrators and allies to “be vocal in pushing back by sharing the ways these proposals would be devastating to their families and the healthcare community at large.” 

The American Civil Liberties Union also condemned the administration’s proposals and vowed to challenge the efforts in court. 

Chase Strangio, co-director of the ACLU’s LGBTQ & HIV Rights Project, dubbed the proposals “cruel and unconstitutional attacks on the rights of transgender youth and their families.” 

Strangio said the proposals would “force doctors to choose between their ethical obligations to their patients and the threat of losing federal funding” and “uproot families who have already fled state-level bans, leaving them with nowhere to turn for the care they need to survive and thrive.”

U.S. Sen. Josh Hawley, R-Mo., talks to reporters at the U.S. Capitol on Saturday, June 28, 2025. (Photo by Ashley Murray/States Newsroom)

WASHINGTON — Missouri U.S. Sen. Josh Hawley is ratcheting up pressure on the U.S. Food and Drug Administration to finish a study into medication abortion and to change its prescribing guidelines, sending a letter to Commissioner Marty Makary on Wednesday that the pace of the review is “totally unacceptable.”

The letter came just one day after leading anti-abortion groups called on President Donald Trump to fire Makary, following a report from Bloomberg Law that he planned to delay the agency’s review into mifepristone until past the November midterm elections. 

Hawley wrote in the two-page letter he posted to social media that it was “unclear” whether the FDA was actually conducting a review of the current prescribing guidelines and the safety of medication abortion. 

“There are more abortions in America now than when Roe was still law,” Hawley wrote, referring to the 1973 Roe v. Wade ruling from the Supreme Court, which established the constitutional right to an abortion. “And this is largely because of the chemical abortion drug and its generics, like the one you approved.”

Hawley asked Makary to reply to three questions before Dec. 15, including whether the FDA is “conducting a comprehensive safety review of mifepristone separate from the (Risk Evaluation and Mitigation Strategies) process,” if Makary delayed any safety reviews of mifepristone and if the FDA has plans to revert prescribing guidelines to require in-person dispensing. 

President Donald Trump, asked about the timeline during a roundtable at the White House, said he would find out whether the FDA was stalling. 

“I’ll find out. I’ll ask them,” Trump said. “I don’t think they’re slow walking anything, but I’ll find out.”

A spokesperson for the Department of Health and Human Services, which includes the FDA, said that “FDA’s comprehensive scientific reviews take the time necessary to get the science right, and that is what Dr. Makary is ensuring as part of the Department’s commitment to gold-standard science and evidence-based reviews.”

Second day of pressure on Makary

Hawley’s letter continued the public pressure campaign from anti-abortion organizations and lawmakers that began Tuesday when leaders at Susan B. Anthony Pro-Life America and Live Action called for Makary to be fired over the Bloomberg Law news story reporting he had delayed the review of mifepristone over political considerations related to the midterm elections.

Americans United for Life CEO John Mize released a statement after meeting with Makary, saying it “is glaringly obvious that flawed political calculations” have stalled the FDA’s review of mifepristone, but not calling for him to lose his job over it. 

Access to mifepristone

Mifepristone is one of two pharmaceuticals used in medication abortion. It is approved for up to 10 weeks gestation and can be prescribed via telehealth and shipped to patients. 

Reducing or eliminating access to mifepristone has become a linchpin of the anti-abortion movement since the U.S. Supreme Court overturned the nationwide right to an abortion in 2022. 

Anti-abortion medical organizations, represented by Alliance Defending Freedom senior counsel Erin Morrow Hawley, tried unsuccessfully to have the Supreme Court revert the prescribing guidelines for mifepristone in 2024. 

Josh Hawley and Erin Morrow Hawley are married. 

Numerous medical organizations, including the American College of Obstetricians and Gynecologists and the American Medical Association, filed briefs to the justices in that case attesting to the safety and efficacy of medication abortion. 

“The scientific evidence is overwhelming: major adverse events occur in less than 0.32% of patients,” the groups wrote. “The risk of death is almost non-existent.”